BioVie Inc.BIVI
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · bioviepharma.com
BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance for Alzheimer's disease, Parkinson's disease and Long COVID, while BIV201 (terlipressin) is being advanced for complications of liver cirrhosis.
Key ratios
ROA
-79.1%TTM
2026
-79.1%2025
-48.3%2024
-66.7%
ROE
-150.8%TTM
2026
-150.8%2025
-101.6%2024
-208.3%
Recent news
BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long Covid
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long COVID
BioVie Announces Update to Parkinson's Phase 3 Development Program
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Track BIVI in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer